Jupiter Neurosciences, Inc. Common Stock (JUNS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.24M
Last updated: Nov 17, 2026 at 4:15 PM ET
Jupiter Neurosciences, Inc. Common Stock (JUNS) Statistics
Jupiter Neurosciences, Inc. Common Stock (JUNS) has a market cap of $2.24M and an enterprise value of $2.17M. It kept -17976.04% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 3.34% below the market cap, as cash exceeds debt.
| Market Cap | $2.24M |
|---|---|
| Enterprise Value | $2.17M |
| Latest price (Nov 17, 2026) | $1.54 |
Key Dates
| Last Earnings Date | Aug 14, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 19.1x.
| P/S Ratio | 19.1x |
|---|---|
| Forward P/S | 0.2x |
Price Statistics
The stock is down 98.47% over 52 weeks and trades 41.67% below its 50-day average.
| Beta (1Y) | 1.61 |
|---|---|
| 52-Week Change | -98.47% |
| 1-Month Change | -44.00% |
| 3-Month Change | -67.92% |
| 6-Month Change | -93.58% |
| Total Return (1Y) | -98.47% |
| Return vs SPY (1Y) | -109.92% |
| Max Drawdown (1Y) | -98.42% |
| Sharpe Ratio (1Y) | -3.29 |
| Correlation with SPY (1Y) | 0.18 |
| 50-Day Average | $2.64 |
| 200-Day Average | $17.16 |
| 52-Week Range | $1.63 to $101.25 |
| RSI (14 Days) | 28.2 |
| Average Volume (20 Days) | 19.08K |
Financial Position
Current assets cover 0.49x current liabilities.
| Current Ratio | 0.49x |
|---|---|
| Quick Ratio | 0.44x |
| Interest Coverage | -30.10x |
Returns and Efficiency
Return on invested capital is 1154.48% over the last 12 months.
| Return on Assets (ROA) | -870.87% |
|---|---|
| Return on Invested Capital (ROIC) | 1154.48% |
| Asset Turnover | 0.04x |
| Inventory Turnover | 0.12x |
| Receivables Turnover | 15.36x |
| Cash Conversion Cycle | -15806 days |
Scores
JUNS has an Altman Z-Score of -68.30, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -68.30 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $78.64K over the last 12 months.
| Revenue | $78.64K |
|---|---|
| Gross Profit | $62.53K |
| Operating Income | -$13.31M |
| Pretax Income | -$14.14M |
| Net Income | -$14.14M |
| EBITDA | -$12.92M |
| EBIT | -$13.68M |
| Reported EPS (TTM) | -$9.59 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $300.62K |
|---|---|
| Total Debt | $225.69K |
| Net Cash | $74.94K |
| Net Cash Per Share | $0.08 |
| Working Capital | -$1.33M |
| Shareholder Equity | -$1.16M |
| Total Assets | $1.62M |
| Total Liabilities | $2.79M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$8.82M |
|---|---|
| FCF Per Share | -$6.69 |
| Depreciation and Amortization | $766.67K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -16926.86%.
| Gross Margin | 79.52% |
|---|---|
| Operating Margin | -16926.86% |
| Pretax Margin | -17976.04% |
| Net Margin | -17976.04% |
| EBITDA Margin | -16425.69% |
| EBIT Margin | -17400.66% |
Growth
Revenue fell 54.62% a year over 3 years.
| Revenue Growth (3Y CAGR) | -54.62% |
|---|---|
| Revenue Growth (5Y CAGR) | -54.57% |
Dividends and Yields
JUNS does not pay a dividend.
| Buyback Yield | -124.42% |
|---|---|
| Shareholder Yield | -124.42% |
Stock Splits
The last split was a 1-for-75 reverse split on Aug 7, 2026.
| Last Split Date | Aug 7, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:75 |
Peer Position
Against 3 similar companies, JUNS has the 2nd highest P/S.
P/S RatioPeer median 2.8x
ROICPeer median -90.21%
| P/S Ratio | 19.1x vs 2.8x median |
|---|---|
| ROIC | 1154.48% vs -90.21% median |
Analyst Forecast
Consensus estimates put revenue growth at 52235.29% a year over the next fiscal year.
| Revenue Growth Forecast (1Y CAGR) | +52235.29% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About JUNS
What is JUNS's market cap?
Jupiter Neurosciences, Inc. Common Stock has a market cap of $2.24M. Its enterprise value, which adds debt and subtracts cash, is $2.17M.
How many shares of JUNS are outstanding?
Jupiter Neurosciences, Inc. Common Stock has 973.63K shares outstanding.
Does JUNS pay a dividend?
No. Jupiter Neurosciences, Inc. Common Stock does not pay a dividend.
How much debt does JUNS have?
Jupiter Neurosciences, Inc. Common Stock has $225.69K of total debt and $300.62K of cash and equivalents, a net cash position of $74.94K.
JUNS pages: Overview, Financials, Statistics, Competitors